Chemotherapy response score is a useful histological predictor of prognosis in high grade serous carcinoma
Histopathology Sep 23, 2017
Singh P, et al. - This trial encompassed the inquiry of chemotherapy response score (CRS) in post neoadjuvant chemotherapy (NACT) cases of high-grade serous carcinoma. In addition, it evaluated the interobserver agreement and aimed at associating it to overall and progression- free survival. CRS was found to be an easy and reproducible method for speculating the prognosis in post NACT high-grade serous carcinoma patients.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
